The pandemic has accelerated the processes of creating an integrated digital information supply chain. It has also intensified the digital development of the drug supply industry by taking the drug manufacture control sector to a new level. This has spurred the launch of an automated system for monitoring drug circulation from the manufacturer to the end user. Consumers now have the opportunity to acquire non-prescription drugs at online stores, marketplaces, and pharmaceutical aggregators. A unified, vertically integrated medical information system, the switch to an electronic medical document flow system, mobile applications, and electronic prescriptions will together lead to a breakthrough, and make drugs more accessible and prevent shortages. An electronic patient register, which will help manage information regarding expenses, treatment status and effectiveness, will allow the government to build a foundation for procurement and targeted drug supply. Today, the digitization of the industry is an essential component of the trend towards a patient-centred healthcare model. Is the digitization of the drug market an end in itself, or rather a tool to improve the quality of drug supply? What digital solutions need to be introduced in the pharma industry to dovetail with this system? To what degree does drug labelling support the interests of regulators, the market, and patients? What are the expectations, and what is the current operational experience? What aspects of digitalizing trade in pharma products need special attention, and what are the initial results of sales by electronic prescriptions in Russias regions? What effective solutions can ensure continuity of drug supply in hard-to-reach and remote areas of the country? How do patients stand to benefit from target notification of their rights and available drug supply?